This effect is avoided with concurrent utilisation of 5α-reductase inhibitors, such as finasteride, or flutamide which function to block the downstream effects of testosterone. Available forms
Leuprorelin is available in the following forms, among others:
Short-acting daily intramuscular injection (Lupron)
Long-acting depot intramuscular injection (Lupron Depot)
Long-acting depot subcutaneous injection (Eligard)
Long-acting subcutaneous injection (Fensolvi)
Long-acting subcutaneous implant (Viadur)
Long-acting leuprolide mesylate (Camcevi) for the treatment of advanced prostate cancer. Leuprolide acetate and norethindrone acetate combination pack (Lupaneta Pack)

Chemistry
The peptide sequence is Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt (Pyr = L-pyroglutamyl). History
Leuprorelin was discovered and first patented in 1973 and was introduced for medical use in 1985. It was initially marketed only for daily injection, but a depot injection formulation was introduced in 1989. Approvals
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on April 9, 1985. Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on January 26, 1989. Viadur was approved by the FDA for palliative treatment of advanced prostate cancer on March 6, 2000. Eligard was approved by the FDA for palliative treatment of advanced prostate cancer on January 24, 2002. Fensolvi was approved by the FDA for children with central precocious puberty on May 4, 2020.
This use is controversial since the Lupron label advises against using the drug when one is considering pregnancy, due to a risk of birth defects.It may be used to reduce the risk of premature ovarian failure in women receiving cyclophosphamide for chemotherapy.Along with triptorelin and goserelin, it has been used to delay puberty in transgender youth until they are old enough to begin hormone replacement therapy. Researchers have recommended puberty blockers after age 12, when the person has developed to Tanner stages 2–3, and then cross-sex hormones treatment at age 16. This use of the drug is off-label, however, not having been approved by the Food and Drug Administration and without data on long-term effects of this use.They are also sometimes used as alternatives to antiandrogens like spironolactone and cyproterone acetate for suppressing testosterone production in transgender women. It also is used for suppressing estrogen production in transgender men.It is considered a possible treatment for paraphilias. Leuprorelin has been tested as a treatment for reducing sexual urges in pedophiles and other cases of paraphilia.